UCB (OTCMKTS:UCBJY) Shares Gap Down – Here’s Why

UCB SA (OTCMKTS:UCBJY) gapped down prior to trading on Monday . The stock had previously closed at $151.41, but opened at $144.48. UCB shares last traded at $144.87, with a volume of 1,975 shares traded.

Analysts Set New Price Targets

Several brokerages have commented on UCBJY. Jefferies Financial Group upgraded shares of UCB to a “moderate sell” rating in a research note on Monday, June 22nd. Barclays cut UCB from a “strong-buy” rating to a “hold” rating in a research report on Monday, June 15th. Finally, Zacks Research downgraded UCB from a “hold” rating to a “strong sell” rating in a research note on Thursday, June 11th. Two investment analysts have rated the stock with a Strong Buy rating, one has issued a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Hold”.

UCB Stock Performance

The company has a debt-to-equity ratio of 0.20, a quick ratio of 1.04 and a current ratio of 1.38. The company’s 50 day simple moving average is $143.51 and its 200 day simple moving average is $147.94.

About UCB

UCB is a global biopharmaceutical company founded in Belgium in 1928, specializing in the discovery and development of therapies for severe diseases in the fields of neurology and immunology. Headquartered in Brussels, UCB leverages nearly a century of scientific expertise to address areas of high unmet medical need, with a focus on chronic conditions such as epilepsy, Parkinson’s disease, rheumatoid arthritis and Crohn’s disease.

The company’s commercial portfolio includes key branded medicines such as CIMZIA (certolizumab pegol) for inflammatory disorders, VIMPAT (lacosamide) for the treatment of partial-onset seizures in epilepsy, and NEUPRO (rotigotine transdermal system) for Parkinson’s disease and restless legs syndrome.